Blueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($0.58), $0.05 worse than the analyst estimate of ($0.53). Revenue for the quarter came in at $4.64 million versus the consensus estimate of $2.85 million.

As of December 31, 2015, cash and cash equivalents were $162.7 million, as compared to $47.2 million as of December 31, 2014. This increase was primarily due to net proceeds of $154.8 million received upon the closing of Blueprint Medicines' initial public offering in May 2015. Blueprint Medicines expects that its existing cash and cash equivalents will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into at least the third quarter of 2017.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.